Abbas, Syed Hussain http://orcid.org/0000-0002-9434-2970
Ceresa, Carlo D. L.
Hodson, Leanne
Nasralla, David
Watson, Christopher J. E.
Mergental, Hynek
Coussios, Constantin
Kaloyirou, Fotini
Brusby, Kerrie
Mora, Ana
Thomas, Helen
Kounali, Daphne
Keen, Katie
Pollok, Joerg-Matthias
Gaurav, Rohit
Iype, Satheesh
Jassem, Wayel
Perera, M. Thamara PR
Hakeem, Abdul Rahman
Knight, Simon
Friend, Peter J.
Funding for this research was provided by:
Efficacy and Mechanism Evaluation Programme (NIHR131163)
Article History
Received: 26 February 2024
Accepted: 22 May 2024
First Online: 17 June 2024
Declarations
:
: The protocol, patient information leaflets, consent form and the supportive paperwork, including the IRAS form, were submitted to the London—Brighton & Sussex Research Ethics Committee for ethics review on 9 March 2022. The REC favourable opinion and the HRA / HCRW approval were obtained on 25 May 2022: 22/LO/0257.
: Informed consent materials are attached as supplementary materials. No identifiable clinical details of participants are presented in this current article or will be presented in the subsequent publication of trial results.
: Peter Friend and Constantin Coussios are co-founders and shareholders in OrganOx (a University of Oxford spinout company). They receive consultancy payments as non-executive chief medical and chief technical officers, respectively, of the company.Simon Knight, David Nasralla and Carlo Ceresa have received consultancy income from OrganOx for assisting with the design and conduct of previous trials. Hynek Mergental is employed by Transmedics who have no involvement or participation in the DeFat study.Peter Friend, Constantin Coussios and Simon Knight will be not be involved in approaching, consenting, recruiting or in the clinical management of patients in the proposed trial (the Oxford Transplant Centre is not a liver transplant unit).